NCT05255484 - Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

LM-108

Administered intravenously

DRUG

An Anti-PD-1 Antibody

Administered intravenously

Trial Locations (6)

Ocala Oncology Center, Ocala

Gabrail Cancer and Research Center, Canton

The Christ Hospital, Cincinnati

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

University of Oklahoma, Norman

Mary Crowley Cancer Research, Dallas